Russian pharmaceutical company Binnopharm, owned by AFK Sistema holding company, and GlaxoSmithKline will sign an agreement on Friday on transferring technologies and antigen supplies to produce innovative vaccines in Russia, Finance Minister Alexei Kudrin said.
"Under the agreement, the parties intend to create a joint scientific and research center," Kudrin told a meeting of Russian-British trade and investment committee.
GlaxoSmithKline will also sign two strategic partnership protocols with the governments of the Vologda region, located in central Russia, and the Tomsk region in Siberia.
Binnopharm specializes in the development and production of genetically engineered drugs, including hepatitis B vaccine.
GlaxoSmithKline, one of the world's leading pharmaceutical companies, has been operating in Russia since the 1980s. In 1997, the corporation set up a joint venture, SmithKline Beecham-Biomed, which is part of Glaxo's global production network.
MOSCOW, November 26 (RIA Novosti)